The B-cell lymphomas differed in their expression levels of the CD20 target antigen and the complement regulatory protein CD59, and lymphomas with a higher CD20/CD59 expression ratio proved to be more sensitive for RTX-mediated CDC. This evidence concerns the gene CD59 and lymphoma.